This paper is only available as a PDF. To read, Please Download here.
Abstract
The soluble CD antigens sCD8, sCD23, and sCD25 are increased in untreated Graves'
hyperthyroidism. These levels remain elevated when euthyroidism is established in
response to propylthiouracil (PTU) therapy but decrease to control values after PTU
treatment is discontinued, when euthyroldlsm has been established and maintained.
Neither sCD8 nor sCD23 are elevated in patients with euthyroid Graves' ophthalmopcrthy
nor in the hyperthyroid phase of subacute thyroidltis. sCD25 is increased to an intermediate
degree in these disorders. Soluble CD8 ≥ 450 U/ml is sensitive, specific, and predictive
of PTU success as sole therapy or need for definitive therapy in untreated and PTU-treated
Graves' hyperthyroidism, exceeding the predictive values of thyroid-stimulating hormone
receptor antibody, thyroid peroxidase antibody, and T3 radioimmunoassay.
Abbreviations:
IL-2R (interleukin-2R), PTU (propylthiouracil), RAI (radioactive iodine), RIA (radioimmunoassay), sCD (soluble cluster of differentiation), TPO (thyroid peroxidase), TSH (thyroid-stimulating hormone), TSHrAb (TSH receptor antibody)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Lymphocyte Fc receptors: the immunobiology and pathology of CD23.Immunobiology. 1992; 185: 235-267
- Spontaneous release of the Leu 2(T8) molecule from human T cells.J Exp Med. 1983; 158: 752-766
- Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE.J Immunol. 1988; 141: 495-499
- Soluble interleukin-2 receptors are shed by activated human lymphocytes in vitro.in: Fed Proc. 44. 1985: 946
- Autoantibodies to the thyrotropin receptor.Endocr Rev. 1988; 9: 106-121
- The soluble interleukin-2 receptor: biology, function and clinical application.Ann Intern Med. 1990; 113: 619-627
- Soluble interleukin-2 receptor in sera of patients with Graves' disease.J Autoimmun. 1991; 4: 681-688
- Serum soluble interleukin-2 receptors in hyperthyroid Graves' disease and effect of carbimazole therapy.Clin Endocrinol. 1990; 33: 317-321
- The effect of carbimazole therapy on interleukin-2, interleukin-2 receptors and free radicals.Autoimmunity. 1990; 8: 3-7
- Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.Clin Exp Immunol. 1992; 88: 405-409
- Soluble CD8 during T cell activation.J Immunol. 1989; 142: 2230-2236
- The molecules controlling B lymphocytes.Immunol Today. 1987; 8: 339-344
- Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients.Blood. 1988; 72: 1015-1021
- Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome.Blood. 1988; 73: 209-213
- Effect of interferon-a on the expression and release of CD23 molecule in hairy cell leukemia.Blood. 1989; 74: 2455-2463
- Immunochemical analysis of the released Leu-2 (T8) molecule.J Exp Med. 1984; 160: 116
- Increased levels of soluble CD8 molecules in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders.Clin Immunol Immunopathol. 1989; 50: 146
- Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations.J Clin Microbiol. 1989; 27: 257-260
- Elevated levels of soluble CD8 molecules in patients with lymphatic filariasis.Immunol Lett. 1990; 26: 85
- Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia.Blood. 1990; 75: 1119-1124
- Soluble CD8 in patients with rheumatic diseases.Clin Exp Immunol. 1990; 80: 354-359
- Soluble CD23 is released by B lymphocytes cycling in response to interleukin-4 and anti-Bp50 (CDW 40).Eur J Immunol. 1988; 18: 349-353
- Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia.Blood. 1988; 71: 94-98
- Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's Syndrome and systemic lupus erythematosus.Clin Exp Immunol. 1992; 89: 452-455
- B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny.Blood. 1990; 76: 1647-1656
- Soluble interleukin-2 receptor in childhood non-Hodgkin's Syndrome.Blood. 1988; 31: 1172-1173
- Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas correlation with survival.J Clin Oncol. 1987; 5: 1262-1267
- Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.Blood. 1987; 71: 1304-1309
- Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of alpha-interferon therapy on clinical parameters and on natural killer in vitro activity.Blood. 1987; 70: 1530-1535
- In vitro activation of T lymphocytes from human immunodeficiency virus (HIV)-seropositive blood donors. I. Soluble interleukin-2 receptor (IL-2R) production parallels cellular IL-2R expression and DNA synthesis.J Clin Immunol. 1988; 8: 114-120
- Elevated interleukin-2 receptor levels in serum of human immunodeficiency virus infected populations.Aids Res Hum Retroviruses. 1988; 4: 115-120
- Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.Clin Exp Immunol. 1990; 82: 75-80
- Plasma interleukin-2 receptor levels in renal allograft recipients.Clin Immunol Immunopathol. 1987; 43: 273-276
- The soluble interleukin-2 receptor in rheumatic disease.Arthritis Rheum. 1990; 33: 1145-1148
- Soluble interleukin-2 receptors: analysis in normal individuals and in certain disease states.in: Fed Proc. 45. 1986: 377
- Prediction of remission after antithyroid drug treatment in Graves' disease.QJ Med. 1988; 250: 175-189
- Is soluble CD25 antigen (interleukin-2 receptor) a useful parameter for differential diagnosis of thyrotoxicosis?.Clin Invest. 1992; 70: 122-124
- Differential immunosuppressive action of carbimazole and propylthiouracil.Clin Exp Immunol. 1988; 73: 312-315
- The ability of the serum thyrotropin antibody (TRAb) index and HLA status to predict long term remission of thyrotoxicosis following medical therapy for Graves' disease.Clin Endocrinol. 1986; 25: 151
- Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: Their incidence, significance and clinical usefulness.Autoimmunity. 1989; 3: 103-112
- Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid disease.FEBS Lett. 1985; 190: 147-152
- The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs.J Clin Endocrinol Metab. 1989; 68: 1093-1100
- Current trends in the management of Graves' disease.J Clin Exp Med. 1990; 70: 1518-1524
- High levels of serum interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.J Clin Endocrinol Metab. 1991; 73: 771-776
Article info
Publication history
Accepted:
February 22,
1994
Received in revised form:
February 21,
1994
Received:
July 29,
1993
Footnotes
☆Supported solely by patients' donations to The Evanston Hospital.
Identification
Copyright
© 1994 Published by Elsevier Inc.